CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
Reproxalap Ophthalmic Solution (0.25%) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05102409
NCT05102409Phase 2Completed
CompareCT.gov

An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects With Dry Eye Disease in a Dry Eye Chamber

Aldeyra Therapeutics, Inc.·interventional·Posted Nov 1, 2021·Updated Feb 28, 2025

In Brief

A Phase 2 clinical trial evaluating Reproxalap Ophthalmic Solution (0.25%) and Xiidra® (5% lifitegrast ophthalmic solution) for Dry Eye. Completed, enrolled 56 participants across 1 site.

Detailed Summary

An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects with Dry Eye Disease in a Dry Eye Chamber

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedNov 1, 2021
Enrollment StartSep 9, 2021
Primary CompletionOct 25, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.7 years ago

Interventions

Reproxalap Ophthalmic Solution (0.25%)drug

Reproxalap Ophthalmic Solution (0.25%) dosed once

Xiidra® (5% lifitegrast ophthalmic solution)drug

Xiidra® (5% lifitegrast ophthalmic solution) dosed once